A high-quality, profitable business with steady sales.
Facts from SEC filings, not a recommendation.
From SF's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
Last 12 months: $6.7B, up 11% from the 12 months before. Over 5 years, sales grew about 11% a year.
Move the sliders to your own view of SF. Starting points are the company's recent numbers.
What today's price needs: with a 14% margin and a 10x P/E, sales would have to grow about 0.7% a year for 5 years just to match today's price.
Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.
Price chart by TradingView.
From annual reports filed with the SEC. Gross margin doesn't apply to banks and insurers, so it isn't scored. Not in this company's SEC data, so not scored: return on equity 15%+, debt under half of equity. A checklist is a starting point for research, not a verdict.
Revenue and EPS as the company states them. Margins, cash flow and share count fill in with the 10-Q.
No open-market insider buys or sells in the last 90 days.
No trades to chart yet.
SEC filings of any kind. 50 means a normal week.
Institutions added 1.4% to their holdings. 246 bought, 345 sold. 3 quarters of net buying in a row.
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
4,700 shares at $79.20 avg ($79.14 to $79.25) · $372K
2,450 shares at $71.40 · $175K
2,450 shares at $71.40 · $175K
Source: SEC EDGAR filings. For informational purposes. Not investment advice.
Report a problem with this page